肿瘤细胞治疗研究
英文原题：Effector-cell-engaging bispecific antibodies for cancer therapeutics: Engineering precision immunity.
双特异性抗体（bsAb）是一种新型免疫治疗平台，由单个分子组成，可同时结合两种不同的抗原，即肿瘤相关抗原和免疫效应细胞，从而增强对肿瘤细胞的靶向杀伤。
双特异性抗体（bsAb）是一种新型免疫治疗平台，由单一分子组成，可同时结合两种不同的抗原，即肿瘤相关抗原和免疫效应细胞，从而增强对肿瘤细胞的靶向杀伤。bsAb可通过CD3、CD16或CD47等受体靶向T细胞和自然杀伤（NK）细胞或巨噬细胞，并产生强大的、不依赖MHC的抗肿瘤活性。本综述概述了效应细胞衔接型bsAb形式的演变，如BiTE、DART、TandAb和IgG样构建体，以及增强Fc功能、效价、半衰期、安全性和有效性的工程策略。文章描述了经临床验证的T细胞衔接器、新型NK细胞和巨噬细胞靶向bsAb、三特异性NK衔接器、肿瘤激活型和mRNA编码的bsAb，以及与检查点抑制剂和细胞疗法的联合策略，重点阐述了它们在精准肿瘤学中的作用。
The bispecific antibody (bsAb) is a novel immune therapeutic platform that consists of a single molecule that simultaneously binds two distinct antigens, tumor-associated antigens and immune effector cells, to enhance the targeted killing of tumor cells. bsAbs can target T cells and natural killer (NK) cells or macrophages through receptors such as CD3, CD16 or CD47 and generate strong, MHC-independent antitumor activity. This review outlines the evolution of effector-cell-engaging bsAb formats, such as BiTEs, DARTs, TandAbs and IgG-like constructs, along with engineering strategies to enhance Fc function, valency, half-life, safety and efficacy. It describes clinically validated T-cell engagers, new NK-cell- and macrophage-targeting bsAbs, trispecific NK engagers, tumor-activated and mRNA-encoded bsAbs, and combination strategies with checkpoint inhibitors and cellular therapies, highlighting their role in precision oncology.
MEMBER ACCOUNT
登录成功会直接打开下一页。
